Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

• Antoni Ribas,
• Alain Algazi,
• Paolo A. Ascierto,
• Marcus O. Butler,
• Sunandana Chandra,
• Michael Gordon,
• Leonel Hernandez-Aya,
• Donald Lawrence,
• Jose Lutzky,
• Wilson H. Miller,
• Katie M. Campbell,
• Bruno Delafont,
• Shannon Marshall,
• Nancy Mueller,
• Caroline Robert

Affiliations

Antoni Ribas

University of California Los Angeles (UCLA) and Jonsson Comprehensive Cancer Center at UCLA

Alain Algazi

UCSF Medical Center

Paolo A. Ascierto

Istituto Nazionale Tumori IRCCS Fondazione Pascale

Marcus O. Butler

Princess Margaret Cancer Centre

Sunandana Chandra

Northwestern Memorial Hospital

Michael Gordon

HonorHealth Research Institute

Leonel Hernandez-Aya

Washington University School of Medicine

Donald Lawrence

Massachusetts General Hospital

Jose Lutzky

Mount Sinai Medical Center

Wilson H. Miller

Segal Cancer Center, Jewish General Hospital, Rossy Cancer Network, McGill University

Katie M. Campbell

University of California Los Angeles (UCLA) and Jonsson Comprehensive Cancer Center at UCLA

Bruno Delafont

AstraZeneca

Shannon Marshall

AstraZeneca

Nancy Mueller

AstraZeneca

Caroline Robert

Gustave Roussy Cancer Campus and Paris-Saclay University